share_log

PureTech Health Plc (OTCMKTS:PTCHF) Short Interest Up 26.3% in November

PureTech Health Plc (OTCMKTS:PTCHF) Short Interest Up 26.3% in November

百泰健康股份有限公司十一月份短期利息上升 26.3%
Financial News Live ·  2022/12/14 19:41

PureTech Health plc (OTCMKTS:PTCHF – Get Rating) was the recipient of a large increase in short interest during the month of November. As of November 30th, there was short interest totalling 159,100 shares, an increase of 26.3% from the November 15th total of 126,000 shares. Based on an average daily volume of 10,300 shares, the days-to-cover ratio is presently 15.4 days.

PureTech Health Plc(場外交易市場代碼:PTCHF-GET Rating)是11月份空頭股數大幅增長的接受者。截至11月30日,空頭股數共有15.91萬股,比11月15日的12.6萬股增加了26.3%。以日均成交量10,300股計算,目前天數與回補比率為15.4天。

PureTech Health Price Performance

PureTech健康性價比

Shares of PTCHF remained flat at $3.40 during midday trading on Wednesday. The company's stock had a trading volume of 3,707 shares, compared to its average volume of 6,311. PureTech Health has a twelve month low of $1.83 and a twelve month high of $4.14. The business has a fifty day simple moving average of $2.89 and a 200 day simple moving average of $2.63.

在週三午盤交易中,PTCHF的股價持平於3.40美元。該公司股票的成交量為3,707股,而其平均成交量為6,311股。PureTech Health的12個月低點為1.83美元,12個月高位為4.14美元。該業務的50日簡單移動均線切入位為2.89美元,200日簡單移動均線切入位為2.63美元。

Get
到達
PureTech Health
PureTech Health
alerts:
警報:

PureTech Health Company Profile

PureTech Health公司簡介

(Get Rating)

(獲取評級)

PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and psychosis in Alzheimer's disease; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; an immunomodulation platform to treat chronic and acute inflammatory disorders; oral therapies based on defined consortia of bacteria is isolated from the human microbiome; and therapies to treat cognitive dysfunction associated with depression, multiple sclerosis, post COVID and ICU, and cancer related conditions.
PureTech Health plc是一家臨床階段的生物治療公司,在美國發現、開發和銷售治療炎症、纖維化和免疫、頑固性癌症、淋巴和胃腸道、神經和神經心理以及其他疾病的藥物。該公司提供靶向M膽鹼乙酰膽鹼受體的KarXT,用於治療阿爾茨海默病的精神分裂症和精神病;用於治療雄激素性脫髮、上皮老化和其他疾病的再生生物學平臺;用於治療慢性和急性炎症性疾病的免疫調節平臺;用於從人體微生物群中分離出基於特定細菌群的口服療法;以及用於治療與抑鬱症、多發性硬化症、COVID後和ICU以及癌症相關疾病相關的認知功能障礙的療法。

Further Reading

進一步閱讀

  • Get a free copy of the StockNews.com research report on PureTech Health (PTCHF)
  • Mullen Automotive Shares Jump After Signing New Partner
  • REV Group Leads Specialty Vehicle Manufacturers Higher
  • NVIDIA vs AMD: Which is better for 2023?
  • Will Nordstrom Stock be the Grinch This Year?
  • Harpoon Therapeutics Remains Volatile After Promising News
  • 免費獲取StockNews.com關於PureTech Health(PTCHF)的研究報告
  • 馬倫汽車簽署新合作夥伴後股價上漲
  • REV集團引領專用車製造商走高
  • NVIDIA VS AMD:2023年哪一種更好?
  • 諾德斯特龍股票公司會成為今年的格林奇嗎?
  • 魚叉治療公司在有希望的消息傳出後仍不穩定

Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.

獲得PureTech HealthDaily的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對PureTech Health和相關公司的最新新聞和分析師評級的每日簡要摘要。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論